Kisspeptin-10 complete guide

Kisspeptin was originally identified in 1996 at Penn State University as a metastasis-suppressor protein — the parent gene was named KISS1 (a nod to the Hershey “Kisses” produced in the same Pennsylvania town), and the peptide product was termed metastin for its anti-metastatic activity in melanoma research models. The full-length precursor protein is processed into a 54-amino-acid mature peptide (KP-54, “metastin”). Foundational research focused on its tumor-suppressor function for nearly a decade, until two simultaneous landmark papers in 2003 transformed the field. de Roux et al. (PNAS) and Seminara et al. (NEJM) independently reported that loss-of-function mutations in GPR54 — the orphan G-protein-coupled receptor for which kisspeptin had recently been identified as the endogenous ligand — caused hypogonadotropic hypogonadism in humans, with absent puberty and undetectable LH/FSH pulsatility despite anatomically intact GnRH neurons.

That single observation re-positioned kisspeptin from an oncology curiosity to one of the most-studied peptides in reproductive endocrinology. KP-10 is the 10-amino-acid C-terminal fragment (Tyr-Asn-Trp-Asn-Ser-Phe-Gly-Leu-Arg-Phe-NH₂) that retains full GPR54 agonism and has become the standard research-compound form. Position it as the upstream master switch of the HPG axis: kisspeptin neurons in the arcuate (ARC) and anteroventral periventricular (AVPV) nuclei drive GnRH neurons, GnRH neurons drive pituitary LH/FSH release, and LH/FSH drive gonadal sex-steroid synthesis. Before kisspeptin, GnRH was thought to sit at the top of the hierarchy; the 2003 discovery added a layer above it, fundamentally restructuring the model of HPG-axis regulation.

Quick reference — Kisspeptin-10 identifiers

Property	Kisspeptin-10 (KP-10)
Class	Active 10-aa C-terminal fragment of KISS1-encoded metastin family
Synonyms	KP-10, metastin(45-54), kisspeptin-10
Sequence (10 aa, C-terminal amide)	Tyr-Asn-Trp-Asn-Ser-Phe-Gly-Leu-Arg-Phe-NH2 (YNWNSFGLRF-NH2)
Receptor target	GPR54 / KISS1R — class-A G-protein-coupled receptor on GnRH neurons
Molecular formula	~C63H83N17O14
Molecular weight	~1302.45 g/mol
CAS number	374675-21-5
Origin	Synthetic active fragment of KISS1-encoded human kisspeptin protein
Plasma half-life (research models)	~4 minutes (short, by design)
Vial strengths (TogoPeptide)	5 mg lyophilized

Origin and structure — KISS1 metastin family

The KISS1 gene (chromosome 1q32) encodes a precursor protein that is proteolytically processed into the mature 54-residue peptide metastin (also called KP-54). The original 1996 Penn State characterization identified KISS1 as a metastasis-suppressor in melanoma research models, and the gene was named for its origin in Hershey, Pennsylvania. Subsequent C-terminal-fragment mapping established that the receptor-binding determinants are concentrated in the last 10 residues of the molecule — specifically the C-terminal Arg-Phe-NH₂ (RFamide) motif that places kisspeptin within the broader RFamide-peptide superfamily.

From this mapping work, four naturally-occurring or research-defined kisspeptin variants are recognized in the published literature, all sharing the identical C-terminal RFamide active region:

• KP-54 (metastin) — full-length 54-aa mature peptide, longest plasma half-life
• KP-14 — 14-aa N-terminally extended fragment
• KP-13 — 13-aa fragment, intermediate stability
• KP-10 — 10-aa minimum active fragment retaining full GPR54 agonism

All four bind GPR54 with comparable affinity in published research. Differences emerge primarily in plasma stability and clearance — longer N-terminal extensions improve resistance to proteolytic degradation but do not increase intrinsic potency. KP-10 is the rational truncation to the minimum agonist sequence: it is the closest synthetic analog of the receptor-binding determinant within the metastin family. The C-terminal amide is functionally important — like other RFamide peptides, the amide group contributes to receptor affinity and mimics the natural amidation pattern of the parent protein.

Mechanism — GPR54 / KISS1R agonism

GPR54 / KISS1R receptor binding

KP-10 binds GPR54 (also designated KISS1R, AXOR12, or hOT7T175 in earlier literature), a class-A (rhodopsin-family) G-protein-coupled receptor. GPR54 is densely expressed on GnRH neurons in the hypothalamus, with additional expression in the pituitary, gonads, and placenta. In published mechanistic research, KP-10 binding triggers Gq-protein coupling and activates phospholipase Cβ, generating inositol trisphosphate (IP₃) and diacylglycerol (DAG). The IP₃-mediated intracellular Ca²⁺ release depolarizes the GnRH neuron and triggers GnRH release into the hypothalamic-pituitary portal circulation. Loss-of-function GPR54 mutations abolish this signal — the receptor is not redundant within the HPG-axis hierarchy.

GnRH pulse generation

The most consequential research finding from the kisspeptin field is that kisspeptin neurons function as the upstream pulse generator that drives GnRH neurons. Before 2003, the cellular substrate of the GnRH pulse generator was unresolved; published research now positions the arcuate-nucleus kisspeptin/neurokinin-B/dynorphin (KNDy) neuron population as the autonomous oscillator that paces GnRH release. KP-10 administration in research-animal models reliably triggers GnRH-mediated LH pulses within minutes, with the magnitude and pattern dependent on dose and administration route. This pharmacological probe has been used in published research to map GnRH neuron responsiveness independent of upstream hypothalamic input.

HPG-axis cascade

The full cascade activated by KP-10 is the canonical hypothalamic-pituitary-gonadal pathway, with kisspeptin sitting one tier above the previously-recognized apex:

• KP-10 → GPR54 on GnRH neurons (hypothalamus)
• GnRH release into portal circulation
• GnRH → GnRH-receptor on gonadotrophs (anterior pituitary)
• LH and FSH secretion in pulsatile pattern
• LH/FSH → gonadal receptors (testes / ovaries)
• Sex-steroid synthesis — testosterone, estradiol, progesterone

Each step is characterized in published research literature with measurable pharmacodynamic endpoints. KP-10 research designs typically use serum LH as the proximal readout (peak within 15-30 minutes of administration in most models), with downstream sex-steroid responses on a longer timescale.

Sex-steroid feedback integration

A defining feature of kisspeptin neurobiology is that kisspeptin neurons integrate sex-steroid feedback — the bidirectional regulation that GnRH neurons themselves cannot perform (GnRH neurons largely lack sex-steroid receptors). Two anatomically and functionally distinct kisspeptin neuron populations are characterized:

• Arcuate nucleus (ARC) — KNDy neurons mediate negative feedback. Rising estradiol/testosterone suppresses ARC kisspeptin expression, dampening GnRH drive. This is the tonic-feedback compartment.
• Anteroventral periventricular nucleus (AVPV) — kisspeptin neurons mediate positive feedback for the preovulatory LH surge in females. Rising estradiol upregulates AVPV kisspeptin expression, generating the GnRH/LH surge that drives ovulation.

This dual-population architecture explains how the HPG axis can simultaneously support tonic gonadotropin secretion (negative feedback) and cyclic ovulatory surges (positive feedback) within the same regulatory framework. KP-10 research designs that target this question use selective ARC vs AVPV stimulation paradigms.

Reproductive research literature

Published research-animal-model and clinical-translational literature on KP-10 covers four primary endpoints. Puberty research documents kisspeptin signaling as the trigger for the pubertal reactivation of the HPG axis — KP-10 administration in pre-pubertal research-animal models advances the timing of LH pulsatility onset, and GPR54 loss-of-function blocks it entirely. Ovulation-induction research uses KP-10 (or KP-54) to drive AVPV-pathway LH surges in research-animal designs, with sex-steroid-priming protocols establishing the feedback dependencies. Fertility research investigates kisspeptin signaling in conditions of disrupted HPG-axis function — hypothalamic amenorrhea, polycystic ovary syndrome, idiopathic hypogonadotropic hypogonadism — using KP-10 as both a probe and an investigational tool. Sex-steroid-synthesis research tracks downstream testosterone, estradiol and progesterone responses as integrated pharmacodynamic readouts of cumulative HPG-axis engagement.

This literature is research-frame characterization. KP-10 has not been approved as a therapy in any jurisdiction, and the published findings are observed in research-design contexts — not reproduced as clinical recommendations.

Pulse-generation research

One of the most-studied questions in the KP-10 literature is the dose-pattern relationship between exogenous kisspeptin administration and downstream GnRH/LH dynamics. Published research-animal studies document that pulsatile KP-10 administration (intermittent boluses with intervening washout windows) preserves the pulsatile GnRH/LH response pattern, while sustained KP-10 exposure (continuous infusion or repeated dosing without recovery) can produce GPR54 desensitization and tachyphylaxis after initial activation. This parallels the classic GnRH-receptor desensitization phenomenon known from the GnRH-agonist literature, but at the upstream GPR54 tier.

The research-design implication is that pulsatile KP-10 protocols are appropriate for studies investigating physiological pulse generation, while continuous-exposure designs are appropriate for studies of receptor desensitization or downregulation. KP-10's short ~4-minute plasma half-life supports pulsatile designs naturally — each administration produces a discrete receptor-stimulation pulse that dissipates within typical inter-pulse windows.

Clinical-translational research

KP-10 (and the longer KP-54) have been investigated in human research-clinical contexts for fertility and HPG-axis disorders. Published work documents kisspeptin-induced LH responses in healthy male and female volunteers, in women with hypothalamic amenorrhea, and in fertility-research protocols where kisspeptin is used as an alternative trigger to human chorionic gonadotropin (HCG) for oocyte maturation in assisted-reproduction research. These are research-clinical-translational investigations conducted under research protocols — they are not approved therapeutic indications and KP-10 is not a clinical drug formulation.

The translational interest is grounded in the mechanistic position: because kisspeptin acts at the upstream GnRH-driving tier, it can stimulate an endogenous GnRH pulse rather than substituting an exogenous one. This is mechanistically distinct from GnRH agonists (which act at the pituitary GnRH-receptor) and from HCG (which acts at the gonadal LH-receptor). Each tier of the cascade is pharmacologically accessible, and the choice depends on the research question.

Kisspeptin variants — KP-54 vs KP-14 vs KP-13 vs KP-10

Property	KP-54 (metastin)	KP-14	KP-13	KP-10
Length (aa)	54	14	13	10
C-terminal RFamide motif	Yes	Yes	Yes	Yes
GPR54 affinity	Full agonism	Full agonism	Full agonism	Full agonism
Plasma half-life (research)	~28 min	~10-15 min	~6-10 min	~4 min
Origin	Mature endogenous peptide	N-terminal extension	N-terminal extension	Minimum active fragment
Research application	Sustained HPG-axis stimulation	Intermediate-half-life designs	Intermediate-half-life designs	Pulse-generation probe; mechanism baseline

Position the four as a research toolkit, not as competitors. KP-10 gives the minimum active receptor probe for short discrete stimulation. KP-54 gives a longer-acting endogenous-mimetic for sustained-signal designs. KP-13 and KP-14 provide intermediate options where pulse and sustained-exposure characteristics need to be balanced. All four interrogate the same GPR54 receptor; the choice is half-life × research design.

Storage and handling

Kisspeptin-10 ships as lyophilized powder. Standard research-handling literature for short hypothalamic peptides documents:

• Lyophilized state: sealed at −20°C, protected from light. Stable for the manufacturer-stated window under proper storage.
• Diluent: bacteriostatic water (0.9% benzyl alcohol) is the standard reconstitution diluent. The benzyl alcohol enables multi-puncture access across the refrigerated reconstituted shelf life.
• Reconstituted state: refrigerate at 2–8°C immediately after reconstitution. Research-handling literature for short kisspeptin-class peptides documents an approximate 14-21 day reconstituted shelf life under refrigeration, shorter than longer GHRH-class analogs because of the reduced overall stability of 10-aa fragments.
• Avoid freeze-thaw cycles after reconstitution. The C-terminal amide and the short-peptide structure are sensitive to repeated phase changes; aggregation, oxidation of the tryptophan residue, and amide-bond hydrolysis are the main degradation pathways.
• Vial inspection: clear, colorless solution after reconstitution. Cloudiness or particulates indicate aggregation or microbial compromise; discard and re-reconstitute fresh.

Each TogoPeptide Kisspeptin-10 shipment includes a per-batch Certificate of Analysis with HPLC purity (target ≥98%), mass-spectrometry identity confirmation, lot number, manufacture date and analysis date. See how to read a COA or reconstitution methodology for handling-protocol details.

Cross-research lines and pairings

Kisspeptin-10 is most-cited in published research alongside related HPG-axis compounds. Common research-design pairings:

• HCG comparison-research framework — HCG (human chorionic gonadotropin) acts at the gonadal LH-receptor, the most downstream tier of the HPG-axis cascade. KP-10 acts at the most upstream tier (GPR54 on GnRH neurons). Pairing the two in research designs allows tier-by-tier dissection of axis responsiveness — a blunted KP-10 response with preserved HCG response localizes a deficit to the hypothalamic-pituitary compartment, while parallel responses suggest gonadal-level limitations. See the HCG product page for the comparison-research counterpart.
• GnRH-axis tier-mapping designs — KP-10 (GPR54 tier) + GnRH agonist (GnRH-receptor tier) + HCG (LH-receptor tier) is the canonical three-tier HPG-axis-probe design. Each compound interrogates a different level of the cascade.
• Sex-steroid feedback designs — KP-10 research designs in estrogen- or testosterone-primed research-animal preparations characterize the ARC vs AVPV feedback compartments. Use the reconstitution calculator for stock-solution standardization across research arms.
• Pulsatile-LH-monitoring designs — frequent serum LH sampling (every 10 minutes across a 4-8 hour window) is the standard pharmacodynamic readout for KP-10 protocols, characterizing both pulse amplitude and inter-pulse interval.

Closing

Kisspeptin-10's research position is unique within the HPG-axis pharmacological toolkit: it is the upstream master switch — one tier above GnRH, two tiers above LH/FSH, three tiers above the gonadal sex-steroid endpoint. Every modification within the kisspeptin variant family (KP-54, KP-14, KP-13) is a half-life adjustment to the same C-terminal RFamide active region. For published research that needs to characterize the upstream tier of the HPG axis — pulse generation, sex-steroid feedback integration, GnRH-driving capacity — KP-10 is the standard pharmacological probe, supported by two decades of literature since the 2003 GPR54-mutation discovery transformed the field.

This guide documents what published peer-reviewed research has investigated. It is structural and mechanism context for laboratory researchers, not therapeutic recommendation, not protocol guidance, not a basis for self-administration of any kind.

Source Kisspeptin-10 for laboratory research:

• Kisspeptin-10 product page — full identifiers, 5 mg vial strength, per-batch COA
• Essentials / HPG-axis research compounds — full category listing

For methodology and laboratory-handling questions, contact our research-supply team at info@togopeptide.com.